Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. Juni 2020 07:00 ET | Quelle: American Oncology Network, LLC

American Oncology Network & Sarah Cannon Research Institute Announce Cancer Research Collaboration

Fort Myers, Fla. & Nashville, Tenn., June 15, 2020 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON), and Sarah Cannon Research Institute (Sarah Cannon) announced today a collaboration to...
18. April 2019 07:30 ET | Quelle: Harpoon Therapeutics

Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T cell Engager (HPN536) in Phase 1/2a Clinical Trial for Ovarian and Other Solid Tumor Cancers

HPN536 is the second TriTAC T cell engager to enter clinical development from the Harpoon pipeline Trial initiated at Sarah Cannon Research Institute in Nashville, Tenn. - a leading drug development...
28. Februar 2018 10:08 ET | Quelle: CicloMed LLC

CicloMed Announces First Patient Dosed with Ciclopirox Prodrug in Phase I Trial in Patients with Advanced Solid Tumors

KANSAS CITY, Mo., Feb. 28, 2018 (GLOBE NEWSWIRE) -- CicloMed LLC, a biotechnology company developing novel treatments for bladder cancer, today announced that the first patient has been dosed in a...